[STUDYING SOME PHARMACOLOGICAL EFFECTS OF NEW 3-HYDROXYPYRIDINE DERIVATIVE].

It was established that a new 3-hydroxypyridine (3-HP) derivative, 2-ethyl-6-methyl-3-hydroxypyridine L-aspartate (3-HP), in small doses (1 and 5 mg/kg) increased physical performance in treadmill and swimming tests on rats. The new substance showed greater or equal effects compared to the reference actoprotector drugs metaprot and ladasten in much higher doses. The gluconeogenesis inhibitor tryptophan significantly (74 ± 5%, p < 0.01) prevented this stimulatory effect of 3-HPA in the treadmill test on rats. 3-HPA at a higher dose (30 mg/kg) had marked antiamnesic effect on various models of amnesia in mice. It was more effective than reference drugs mexidol (another 3-HP derivative) in a dose of 30 mg/kg and nootropic drug piracetam in a dose of 200 mg/kg, but had equal effect with these drugs in doses of 50 and 800 mg/kg, respectively. 3-HPA (30 mg/kg per day) had neuroprotective effect in rats with brain ischemia and decreased the neurologic deficiency more effectively than mexidol (50 mg/kg per day).

[VESTIBULAR AND THERMOPROTECTIVE PROPERTIES OF A NEW ACTOPROTECTOR].

In experiments with rats, a new 3-hydroxypyridine (3-HP) derivative--2-ethyl-6-methyl-3-hydroxypyridine L-asparaginate (30 mg/kg)--exhibited a strong vestibuloprotective effect which was better than of promethazine (50 mg/kg), a well-known vestibuloprotector Besides the new actoprotector was competitive with another 3-HP derivative, namely, mexidol (ethyl-methyl-hydroxypyridine succinate) (100 mg/kg). Moreover, a distinct thermoprotective effect of 2-ethyl-6-methyl-3-hydroxypyridine L-asparaginate (30 mg/kg) in mice was not worse than that of mexidol or metaprot (ethylthiobenzimidasol, former name bimethy), an actoprotector with good thermoprotective properties. To conclude, owing to the membrane-protective and antioxidative qualities, the vestibuloprotective and thermoprotective properties of 2-ethyl-6-methyl-3-hydroxypyridine L-asparaginate are better or competitive with the reference preparations.

[Experimental evaluation of actoprotective activity of nitrogen-containing heterocyclic compounds derivatives in extreme conditions].

In experiments on nonlinear male mice the ability of new derivatives of nitrogen-containing heterocyclic compounds to increase the physical working capacity in conditions of hyperthermia, hypothermia and acute normobaric hypoxia and hypercapnia has been investigated. It is established, that pyridine derivative IBHF-11 has more expressed positive action in the said conditions. It provided increase of the working capacity of animals at all kinds of extreme influence, and the value of positive action was comparable, and in conditions of acute normobaric hypoxia and hypercapnia exceeded those at the reference products bemitil and bromantan.

[Studies on actoprotective and antihypoxic properties of new succinate-containing benzothiazole derivatives].

Experiments with mice demonstrated that in contrast to the preparations for comparison (mexidol and reference antihypoxant succinate amtisol at a dose of 1-100 mg/kg) new succinate-containing derivatives of benzothiazole BTI-2 (0.5-5 mg/kg), BTI-3 (0.1, 0.5 and 10 mg/kg), 877-4 (0.5 mg/kg) and BTI-5 (0.5 and 1 mg/kg) improved physical performance of animals by 18-56 and 21-39% in the treadmill test and swimming test (positive effect of BTI-4 and -5 only), respectively. In all three models of acute hypoxia (normobaric hypoxic hypoxia with hyperkapnia, histotoxic and hemic) an obvious antihypoxic activity was displayed by BTI-1 and -2 only. In comparison with mexidol and succinate amtizol, positive and stronger effect of these compounds was achieved at significantly lower doses. Therefore, the succinate-containing benzothiazole derivatives have considerable promise as ingredients of performance enhancing antihypoxic and therapeutic compositions.

[Comparative study of the influence of succinate-containing preparations on mitochondrial respiration in rat brain cells].

It has been established by polarographic measurements that preparations containing succinate, such as cytoflavin (0.85 mM succinate), mexidol, and amtizol succinate (at a concentration of 0.85 mM) but not reamberin (0.045 mM succinate), nearly equally (by 35-45%) increase oxygen consumption in rat brain mitochondria. On the other hand, malonate - inhibitor of the respiratory complex II (succinate dehydrogenase) of mitochondrial chain suppressed the stimulating effect of these drugs.

[Comparative studies of antihypoxic, neuroprotective and analgesic action of succinate-containing drugs].

Experiments with mice showed that, unlike reamberin (100 mg/kg), mexidol (100 mg/kg) and cytoflavin (1 ml/kg) act as antihypoxants in pressure and hermetic chambers but not in case of acute hemic and histotoxic hypoxia. Amtisol succinate (100 mg/kg), a reference antihypoxant, excels the other tried succinate-containing drugs in all models of acute hypoxia except the hermetic chamber. In addition, the neuroprotective action of mexidol (100 mg/kg/d) and cytoflavin (100 ml/kg/d) in rats with induced ischemic stroke which was stronger than that of reamberin and amtisol succinate (100 mg/kg/d). Besides, mexidol (100 mg/kg) but not cytoflavin (1 ml/kg), reamberin or amtisol succinate (100 mg/kg) had a distinct analgesic effect in rabbits. On the neuronal level, mexidol interacts with the GABAA- benzodiazepine-receptor complex in nearly 60% cells and inhibits ion currents through the NMDA-receptor ion channels in nearly 80% neurons.

[Actiprotective and antihypoxic action of new heteroaromatic antioxidants].

Expernents with mice showed that most of 15 new heteroaromatic antioxidant compounds possess aciprotective and antixopixic properties. Based on results of treadmill and swimming tests, actiprotective action of IBKhF-1, 11 and 14 surpassed greatly bemythil and bromanthane in ordinary conditions. Inhibitor of gluconeogenase tryptophan cancelled largely the stimulatting action of highly effective and active IBKhF-1, 2 and 11 on physical performance during treadmill exercise. Consequently, gluconeogenesis activation is one of the major components of the actiprotective action of these antioxidants. In addition, IBKhF-1, 11 and 14 excelled bemythil and bromanthane in the extreme conditions of running in hyperthermia and swimming in acute hypoxia combined with hypercapnia. IBKhF-2 and 14 were better than amtisol (standard antihypoxic agent) and bemythil against acute hypoxia in pressure chamber, whereas IBKhF-4 and 14 excelled these agents in thermal chamber.